Takeda is walking away from the last target in a collaboration with Wave Life Sciences into which the Japanese pharma has already sunk $260 million over the past six years. The decision leaves Wave holding a Huntington’s disease program that it says has caught the attention of other drug developers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,